X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (235) 235
hygiene (235) 235
medical or veterinary science (235) 235
preparations for medical, dental, or toilet purposes (234) 234
specific therapeutic activity of chemical compounds ormedicinal preparations (195) 195
chemistry (174) 174
metallurgy (174) 174
organic chemistry (174) 174
heterocyclic compounds (164) 164
index medicus (33) 33
humans (29) 29
animals (20) 20
biochemistry (20) 20
beer (18) 18
compositions or test papers therefor (18) 18
condition-responsive control in microbiological orenzymological processes (18) 18
enzymology (18) 18
measuring or testing processes involving enzymes, nucleicacids or microorganisms (18) 18
microbiology (18) 18
mutation or genetic engineering (18) 18
processes of preparing such compositions (18) 18
spirits (18) 18
vinegar (18) 18
wine (18) 18
mice (14) 14
biochemistry & molecular biology (13) 13
oncology (13) 13
cancer (12) 12
investigating or analysing materials by determining theirchemical or physical properties (12) 12
measuring (12) 12
mutation (12) 12
physics (12) 12
testing (12) 12
cell line, tumor (11) 11
peptides (11) 11
phosphorylation (10) 10
methylation (9) 9
tumors (9) 9
enhancer of zeste homolog 2 protein (8) 8
gene expression (8) 8
signal transduction (8) 8
antineoplastic agents - pharmacology (7) 7
enhancer of zeste homolog 2 protein - antagonists & inhibitors (7) 7
female (7) 7
intracellular signaling peptides and proteins (7) 7
lymphoma (7) 7
lymphomas (7) 7
protein tyrosine phosphatase, non-receptor type 11 (7) 7
research (7) 7
somatic mutations (7) 7
activation (6) 6
apoptosis (6) 6
b-cell lymphomas (6) 6
ezh2 (6) 6
h3k27 (6) 6
histones - metabolism (6) 6
polycomb repressive complex 2 - genetics (6) 6
polycomb repressive complex 2 - metabolism (6) 6
proliferation (6) 6
protein tyrosine phosphatases - genetics (6) 6
protein tyrosine phosphatases - metabolism (6) 6
proteins (6) 6
sh2 domain-containing protein tyrosine phosphatases (6) 6
xenograft model antitumor assays (6) 6
analysis (5) 5
cell biology (5) 5
cell proliferation - drug effects (5) 5
drug discovery (5) 5
genetic aspects (5) 5
histone methyltransferase (5) 5
histones (5) 5
male (5) 5
methyltransferases (5) 5
polycomb repressive complex 2 - antagonists & inhibitors (5) 5
protein tyrosine phosphatase, non-receptor type 6 (5) 5
selective-inhibition (5) 5
src homology domains (5) 5
anticancer properties (4) 4
care and treatment (4) 4
cell cycle - drug effects (4) 4
cell line (4) 4
cell lines (4) 4
enhancer of zeste homolog 2 protein - genetics (4) 4
enhancer of zeste homolog 2 protein - metabolism (4) 4
enzymes (4) 4
gene expression regulation, neoplastic - drug effects (4) 4
gene-expression (4) 4
growth-factor receptor (4) 4
hek293 cells (4) 4
histone h3 (4) 4
inhibition (4) 4
lysine 27 (4) 4
medicine (4) 4
methyltransferase (4) 4
mice, scid (4) 4
multidisciplinary sciences (4) 4
point mutation (4) 4
protein methyltransferases (4) 4
protein structure, tertiary (4) 4
protein tyrosine phosphatases - chemistry (4) 4
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (275) 275
French (67) 67
German (34) 34
Spanish (21) 21
Chinese (18) 18
Korean (13) 13
Portuguese (8) 8
Japanese (5) 5
Danish (3) 3
Croatian (2) 2
Hungarian (2) 2
Polish (2) 2
Serbian (2) 2
Slovenian (2) 2
Greek (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Methods in Molecular Biology, ISSN 1064-3745, 2017, Volume 1608, pp. 321 - 336
Journal Article
Cancer Genetics, ISSN 2210-7762, 2014, Volume 207, Issue 9, pp. 452 - 453
Journal Article
Nature Chemical Biology, ISSN 1552-4450, 2012, Volume 8, Issue 11, pp. 890 - 896
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 5/2013, Volume 110, Issue 19, pp. 7922 - 7927
Journal Article
The Lancet Oncology, ISSN 1470-2045, 05/2018, Volume 19, Issue 5, pp. 649 - 659
Journal Article
Nature Medicine, ISSN 1078-8956, 11/2015, Volume 21, Issue 11, pp. 1344 - 1349
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 05/2017, Volume 16, Issue 5, pp. 850 - 860
The SWI/SNF complex is a major regulator of gene expression and is increasingly thought to play an important role in human cancer, as evidenced by the high... 
TRANSFORMATION | LUNG-CANCER | METHYLATION | ONCOLOGY | SWI/SNF COMPLEXES | BRG1/BRM | RHABDOID TUMOR | LYMPHOMA | SCREENS | MUTATIONS | EXPRESSION | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Carcinoma, Small Cell - genetics | Humans | Ovarian Neoplasms - pathology | Rhabdoid Tumor - pathology | Ovarian Neoplasms - genetics | Female | Hypercalcemia - drug therapy | Gene Expression Regulation, Neoplastic - drug effects | Nuclear Proteins - genetics | DNA Helicases - genetics | Ovarian Neoplasms - drug therapy | Hypercalcemia - genetics | Rhabdoid Tumor - drug therapy | Diagnosis, Differential | Enhancer of Zeste Homolog 2 Protein - genetics | Histone-Lysine N-Methyltransferase - genetics | Hypercalcemia - pathology | Ovarian Neoplasms - diagnosis | Carcinoma, Small Cell - drug therapy | Transcription Factors - genetics | Carcinoma, Small Cell - diagnosis | Chromosomal Proteins, Non-Histone - genetics | Xenograft Model Antitumor Assays | Animals | Rhabdoid Tumor - genetics | Hypercalcemia - diagnosis | Cell Line, Tumor | Mice | Rhabdoid Tumor - diagnosis | Mutation | Carcinoma, Small Cell - pathology | Medical research | Biotechnology | Ovarian carcinoma | Clinical trials | Tumor cell lines | Gene expression | Anticancer properties | Hypercalcemia | Cell lines | SWI/SNF complex | Xenografts | Histone methyltransferase | Antitumor activity | Inhibition | Cancer | Tumors | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, pp. e0158888 - e0158888
The catalytic activities of covalent and ATP-dependent chromatin remodeling are central to regulating the conformational state of chromatin and the resultant... 
SOFT-TISSUE TUMORS | FUSION | SWI/SNF COMPLEXES | MULTIDISCIPLINARY SCIENCES | GENES | PROLIFERATION | H3K27 | IDENTIFICATION | CANCER | CYTOGENETICS | SYT | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Enhancer of Zeste Homolog 2 Protein - genetics | Enhancer of Zeste Homolog 2 Protein - metabolism | Oncogene Proteins, Fusion - metabolism | Polycomb Repressive Complex 2 - genetics | Humans | SMARCB1 Protein - genetics | Sarcoma, Synovial - metabolism | Xenograft Model Antitumor Assays | SMARCB1 Protein - metabolism | Animals | Sarcoma, Synovial - genetics | Mice, Nude | Oncogene Proteins, Fusion - genetics | Sarcoma, Synovial - drug therapy | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Mice | Mice, Inbred BALB C | Polycomb Repressive Complex 2 - metabolism | Development and progression | Care and treatment | Genetic aspects | Research | Sarcoma | Gene expression | Animal models | Sucrose | Transcription | Xenotransplantation | Methyltransferase | Homeostasis | Metastasis | Anticancer properties | Proteins | Antitumor agents | Enzymatic activity | Xenografts | Inhibition | Catalysis | Fusion protein | Chromosomes | Sugars | Synovial sarcoma | Pharmacology | Bioavailability | Substrates | Chromatin remodeling | Polycomb group proteins | Lysine | Cell death | Medical prognosis | SWI/SNF complex | Mutation | Methylation | Histone H3 | Tumors | Cancer | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2014, Volume 9, Issue 12, pp. e111840 - e111840
Patients with non-Hodgkin lymphoma (NHL) are treated today with a cocktail of drugs referred to as CHOP (Cyclophosphamide, Hydroxyldaunorubicin, Oncovin, and... 
PROTEIN METHYLTRANSFERASES | SELECTIVE-INHIBITION | MOLECULAR SUBTYPES | APOPTOSIS | B-CELL LYMPHOMA | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | RESISTANCE | MECHANISMS | CANCER | SOMATIC MUTATIONS | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Neoplasm Transplantation | Vincristine - pharmacology | Humans | Receptors, Glucocorticoid - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Receptors, Glucocorticoid - agonists | Dexamethasone - pharmacology | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Drug Evaluation, Preclinical | Lymphoma, Non-Hodgkin - drug therapy | Enhancer of Zeste Homolog 2 Protein - metabolism | Random Allocation | Mice, SCID | Prednisolone - pharmacology | Animals | Cyclophosphamide - pharmacology | Lymphoma, Non-Hodgkin - metabolism | Cell Line, Tumor | Glucocorticoids - pharmacology | Prednisone - pharmacology | Doxorubicin - pharmacology | Pyridones - pharmacology | Care and treatment | Corticosteroids | Fluocinolone acetonide | Central nervous system depressants | Analysis | Histones | Models | Non-Hodgkin's lymphomas | Immunosuppressive agents | Steroids | Cancer | Signal transduction | Enzymes | Cell growth | Glucocorticoids | Research & development--R&D | Lymphomas | Mutation | Gene expression | Apoptosis | Index Medicus | Research & development | R&D
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 11/2017, Volume 16, Issue 11, pp. 2586 - 2597
Journal Article
Cancer Research, ISSN 0008-5472, 12/2017, Volume 77, Issue 23, pp. 6651 - 6666
Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a major hurdle in improving the management of clear cell renal cell... 
MEK INHIBITION | MODELS | ONCOLOGY | EPIGENETIC MODIFICATIONS | KINASE INHIBITORS | MECHANISMS | PROLIFERATION | DRUG-RESISTANCE | CANCER | EXPRESSION | EMT | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Lung Neoplasms - drug therapy | Bevacizumab - pharmacology | Phosphorylation | Humans | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Sunitinib | Lung Neoplasms - secondary | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Enhancer of Zeste Homolog 2 Protein - genetics | Enhancer of Zeste Homolog 2 Protein - metabolism | Carcinoma, Renal Cell - pathology | Mice, SCID | Receptor Protein-Tyrosine Kinases - metabolism | Mice, Inbred ICR | Xenograft Model Antitumor Assays | Pyrroles - pharmacology | Animals | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Kidney Neoplasms - pathology | Mice | Kidney Neoplasms - drug therapy | Drug Resistance, Neoplasm - physiology | Tyrosine | Syngeneic grafts | Gene expression | Drug resistance | Anticancer properties | Bevacizumab | Metastases | Allografts | Antiangiogenics | Xenografts | Impact resistance | Histone methyltransferase | Protein-tyrosine kinase receptors | Antitumor activity | Vascular endothelial growth factor | Protein-tyrosine kinase | Clear cell-type renal cell carcinoma | Apoptosis | Cancer | Index Medicus | sunitinib | renal cell carcinoma | kinome reprogramming | patient-derived xenograft | resistance | EZH2
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 4520 - 4520
Enhancer of Zeste Homolog 2 (EZH2) is a catalytic core subunit of the Polycomb repressive complex 2, PRC2. EZH2 catalyzes the tri-methylation of lysine 27 on... 
Journal Article